Get startedLog in
    Picture of Gensight Biologics SA logo

    SIGHT — Gensight Biologics SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapMomentum Trap
    All News

    Brief: Gensight Biologics Announces Five-Year Efficacy And Safety Results For Lumevoq® Gene Therapy

    Picture of Gensight Biologics SA logoGensight Biologics SA
    12/02/2025 06:38
    Feb 12 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * ANNOUNCES FIVE-YEAR EFFICACY AND SAFETY RESULTS FOR
LUMEVOQ®
GENE THERAPY AT CONCLUSION OF REFLECT STUDY
    * 75% OF BILATERALLY TREATED PATIENTS EXPERIENCED CLINICALLY
RELEVANT RECOVERY* OF VISUAL ACUITY VERSUS THEIR NADIR
    * SUSTAINED EFFICACY 5 YEARS AFTER INJECTION IN REFLECT
PHASE III
TRIAL
    * FAVORABLE SAFETY PROFILE CONFIRMED AT 5 YEARS

Source text:  ID:nBwbGLh1la 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Gensight Biologics SA

    See all news